ArticleJournal of fluorescence2026
Establishment of a Time-Resolved Fluoroimmunoassay for sC5b-9 and Validation in Lupus Nephritis.
Article in Journal of fluorescence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to develop a time-resolved fluoroimmunoassay (TRFIA) for the quantitative detection of soluble terminal complement complex (sC5b-9) and to evaluate the clinical significance of urinary sC5b-9 in patients with lupus nephritis (LN). The sC5b-9-TRFIA was established using a 96-well microplate coated with anti-sC5b-9 monoclonal antibody, anti-sC5b-9 polyclonal antibody, and Eu³⁺-labeled goat anti-rabbit IgG. Urinary sC5b-9 levels were determined in 42 patients with LN and 18 healthy controls to further assess its diagnostic potential in LN. The assay demonstrated a detection limit of 1.38 ng/mL and a linear measurement range of 6.25-1000 ng/mL. The intra-assay and inter-assay coefficients of variation ranged from 4.84% to 7.91% and from 7.06% to 9.11%, respectively, indicating good precision. The sC5b-9-TRFIA showed strong agreement with commercially available enzyme-linked immunosorbent assay (ELISA) kits within the same detection range (P < 0.0001). Urinary sC5b-9 concentrations were significantly elevated in LN patients (157.45 ± 127 ng/mL) compared with healthy controls (38.87 ± 30.11 ng/mL, P < 0.0001). In summary, a wide-range sC5b-9 TRFIA based on europium (Eu³⁺) chelate labeling was successfully developed, providing a sensitive and reliable method for assessing the clinical condition of LN.
Indexed as
Identifiers
41272252What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.